In addition, Sig-1R activation is cardioprotective in preclinical models of cardiac injury such as myocardial ischemia-reperfusion injury (IRI), heart failure (HF), hypertrophy, cardiac fibrosis, cardiomyopathy, and cardiovascular complications associated with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection [16,17,18,19,20,21,22,23,24,25,26,27,28,29]. This evidence concerns the gene SIGMAR1 and COVID-19.